TNFRSF8

Across TCGA pan-cancer cohorts, TNFRSF8 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TNFRSF8 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TNFRSF8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNFRSF8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, DLBC, and UCEC are the cancer types where TNFRSF8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	III,IV	0.082	0.548	.003	24	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.030	8	view →
SKCM	OS	Median	IV	0.179	0.727	<.001	7	view →
ESCA	OS	Median	All	0.080	0.681	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.086	0.429	.003	6	view →
BLCA	DFS	Median	III,IV	0.210	0.574	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TNFRSF8–SCLC (DFS)

Open the SCLC breakdown →